Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 5.4% - Should You Buy?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price was up 5.4% on Friday . The company traded as high as $4.33 and last traded at $4.33. Approximately 105,822 shares were traded during trading, a decline of 92% from the average daily volume of 1,354,945 shares. The stock had previously closed at $4.11.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Autolus Therapeutics has an average rating of "Moderate Buy" and an average price target of $8.70.

Autolus Therapeutics Stock Performance

The stock has a market cap of $1.10 billion, a PE ratio of -3.57 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a 50-day simple moving average of $3.88 and a 200-day simple moving average of $4.19.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). Equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC purchased a new position in Autolus Therapeutics in the 2nd quarter worth approximately $43,000. Daiwa Securities Group Inc. grew its holdings in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new stake in Autolus Therapeutics during the 3rd quarter worth $91,000. Bayesian Capital Management LP acquired a new position in Autolus Therapeutics in the 1st quarter worth $100,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in Autolus Therapeutics in the 1st quarter valued at about $108,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.